DOCSLIB.ORG

Disclosure Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disclosure Information Disclosure of Financial Relationships with Commercial Interests Disclosure Policy Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners. In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME’s validation of clinical content statements. BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly. Drug/Device Status Disclosure Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law. Baylor College of Medicine requires that all faculty/presenters disclose an unlabeled use or investigational use of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients. Presenters Disclosures – Financial Relationships The following faculty/presenters/conference moderators have reported that she/he has/had financial relationships with commercial interests (drug/device companies): Abman, Steven*‡ Yes - Financial Interest; Shire:Grant/Research Support (including support for clinical trials)|Shire:Consultancy|United Therapeutics:Grant/Research Support (including support for clinical trials) Abuabara, Katrina* Yes - Financial Interest; TARGET Pharma:Consultancy Abuzzahab, Mary* Yes - Financial Interest; Ascendis:Grant/Research Support (including support for clinical trials)|Soleno:Grant/Research Support (including support for clinical trials)|AstraZeneca:Grant/Research Support (including support for clinical trials)|NovoNordisk: Ackerman, Kate*# Yes - Financial Interest; ONYBiotech:Consultancy Adi, Saleh‡ Yes - Financial Interest; Dexcom:Speakers Bureau Membership|Dexcom:Ownership Interests (stock or stock options; excluding diversified mutual funds)|Dexcom:Honorarium Recipient|Tandem Diabetes Care:Ownership Interests (stock or stock options; excluding div Akers, Aletha*¤ Yes - Financial Interest; Bayer Healthcare:Grant/Research Support (including support for clinical trials)|Templeton Foundation:Grant/Research Support (including support for clinical trials)|Merck Inc:Advisory Committee Membership|Women's Way:Board Members Albertine, KH* Yes - Financial Interest; Shire Pharmaceutical:Grant/Research Support (including support for clinical trials)|United Therapeutic:Grant/Research Support (including support for clinical trials) Aligne, C* Yes - Financial Interest; Merck:Speakers Bureau Membership Ambalavanan, Yes - Financial Interest; SHIRE:Advisory Committee Membership Namasivayam* Anderson, Larry* Yes - Financial Interest; Bavarian Nordic:Consultancy|Phizer:Grant/Research Support (including support for clinical trials)|Novavax:Consultancy|Daiichi-Sankyo:Consultancy * Presenter # Moderator † SIG Chair ‡ Session Chair ¥ Planner-Owner ¤ Workshop Leader Δ Operating Committee ᴧ Program Committee § PAS Staff 1 Disclosure of Financial Relationships with Commercial Interests Anderson, Marsha¥ᴧ Yes - Financial Interest; American Psychiatric Press/Journal of Neuropsychiatry (Spouse):Advisory Committee Membership|Cambridge University Press (Spouse):Intellectual Property (patent rights, royalty payments)|Bayer Corporation (Spouse):Grant/Research Su Andrews, Bree*¤ Yes - Financial Interest; Preeme+You:Advisory Committee Membership Antommaria, Armand# Yes - Financial Interest; Amicus Therapeutics :Consultancy Arai, Katsuhiro¥ᴧ Yes - Financial Interest; Nippon Kayaku CO., LTD:Grant/Research Support (including support for clinical trials)|Mitsubishi Tanabe Pharma Corporation:Honorarium Recipient|EA Pharma CO., LTD:Honorarium Recipient|Kyorin Pharmaceutical CO., LTD:Honorarium Rec Armstrong, Aimee* Yes - Financial Interest; Abbott:Consultancy Arslanian, Silva* Yes - Financial Interest; Eli Lilly and Co.:Grant/Research Support (including support for clinical trials)|Novo Nordisk:Grant/Research Support (including support for clinical trials)|Boehringer-Ingelheim:Board Membership|Astra Zeneca:Board Membership Aschner, Judy*#‡ Yes - Financial Interest; shire pharmaceuticals:Consultancy|gilead:Ownership Interests (stock or stock options; excluding diversified mutual funds) Ashok, Dhandapani* Yes - Financial Interest; Alexion Pharma:Honorarium Recipient|Abbvie Pharma:Honorarium Recipient|Janssen Canada:Honorarium Recipient Ashraf, Ambika* Yes - Financial Interest; Opko:Grant/Research Support (including support for clinical trials)|Ultragenyx:Speakers Bureau Membership|Pfizer:Speakers Bureau Membership|Bristol Mayer Squibb:Speakers Bureau Membership|Celgene:Speakers Bureau Membership|Insys Askenazi, David* Yes - Financial Interest; baxter:Speakers Bureau Membership|aki foundation:Speakers Bureau Membership Asselin, Jeanette* Yes - Financial Interest; AerogenPharma:Employment Atkinson, Meredith* Yes - Financial Interest; AstraZeneca:Employment Axelrod, David* Yes - Financial Interest; Lighthaus Inc.:Ownership Interests (stock or stock options; excluding diversified mutual funds) Bachrach, Laura‡ Yes - Financial Interest; Myovant:Consultancy Backeljauw, Philippe* Yes - Financial Interest; Novo Nordisk:Grant/Research Support (including support for clinical trials)|Ipsen:Grant/Research Support (including support for clinical trials)|Opko:Grant/Research Support (including support for clinical trials)|Sandoz:Grant/Res Bailey, Michael* Yes - Financial Interest; Scioto Biosciences:Ownership Interests (stock or stock options; excluding diversified mutual funds) Bancalari, Eduardo* Yes - Financial Interest; Vyaire:Intellectual Property (patent rights, royalty payments)|Vyaire:Grant/Research Support (including support for clinical trials) Bateman, Brian* Yes - Financial Interest; Aetion:Consultancy|Alosa:Consultancy|Baxalta:Grant/Research Support (including support for clinical trials)|Lilly:Grant/Research Support (including support for clinical trials)|GSK:Grant/Research Support (including support for cl Baum, Michelle A.* Yes - Financial Interest; Retrophin:Advisory Committee Membership|Dicerna:Advisory Committee Membership Beidas, Rinad* Yes - Financial Interest; Oxford University Press:Intellectual Property (patent rights, royalty payments)|Camden Coalition of Healthcare Providers:Consultancy Benfield, Mark‡ Yes - Financial Interest; Mallinckrodt:Grant/Research Support (including support for clinical trials)|Mallinckrodt:Speakers Bureau Membership|Horizon:Speakers Bureau Membership Bennett, Amanda* Yes - Financial Interest; Autism Speaks:Grant/Research Support (including support for clinical trials)|Stemina Biomarker Discovery:Grant/Research Support (including support for clinical trials)|Neurim Pharmaceuticals:Grant/Research Support (including supp Bennett, Kevin* Yes - Financial Interest; Sindri Technologies:Intellectual Property (patent rights, royalty payments)|Nephrodiagnostics LLC:Intellectual Property (patent rights, royalty payments) Benz, Lisa*† Yes - Financial Interest; LSI:Employment|Halyard Health:Employment Berman, Darren* Yes - Financial Interest; Medtronic:Consultancy|Edwards Life Sciences:Consultancy|Abbott:Consultancy Bernstein, Daniel* Yes - Financial Interest; Regencor:Ownership Interests (stock or stock options; excluding diversified mutual funds) Beukelman, Timothy* Yes - Financial Interest; UCB:Consultancy|Novartis:Consultancy Biniwale, Manoj*¤ Yes - Financial Interest; Chiesi Farmaceutici S.p.A. Italy:Grant/Research Support (including support for clinical trials)|Vyaire Medical, USA:Grant/Research Support (including support for clinical trials)|Menzies Institute for Medical Research, Australia: Binns, Helen* Yes - Financial Interest; Magellan Diagnostics, Inc:Consultancy Biondi, Eric*
Load more

Recommended publications
  • List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company
    List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Algeria Bayer Algerie S.P.A. Argentina Bayer S.A. Argentina Biagro S.A. Argentina Monsanto Argentina SRL Australia Bayer Australia Limited Australia Bayer CropScience Holdings Pty Ltd Australia Bayer CropScience Pty Limited Australia Cotton Growers Services Pty. Limited Australia Imaxeon Pty. Ltd. Australia Monsanto Australia Pty Ltd Bangladesh Bayer CropScience Ltd. Belgium Bayer Agriculture BVBA Belgium Bayer CropScience NV Belgium Bayer NV Bermuda MonSure Limited Bolivia Bayer Boliviana Ltda Bolivia Monsanto Bolivia S.A. Bosnia & Herzeg. Bayer d.o.o. Sarajevo Brazil Alkagro do Brasil Ltda Brazil Bayer S.A. Brazil D&PL Brasil Ltda Brazil Monsanto do Brasil Ltda. Brazil Rede Agro Fidelidade e Intermediacao S.A. Brazil Schering do Brasil Química e Farmacêutica Ltda. Brazil Stoneville Brasil Ltda. Bulgaria Bayer Bulgaria EOOD Burkina Faso Monsanto Burkina Faso SARL Chile Bayer Finance & Portfolio Management S.A. Chile Bayer Finance Ltda. Chile Bayer S.A. Chile Monsanto Chile, S.A. Costa Rica Bayer Business Services Costa Rica, SRL Costa Rica Bayer Medical S.R.L. Costa Rica Bayer S.A. Curacao Pianosa B.V. Germany Adverio Pharma GmbH - 1 - List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Germany AgrEvo Verwaltungsgesellschaft mbH Germany Alcafleu Management GmbH & Co. KG Germany BGI Deutschland GmbH Germany Bayer 04 Immobilien GmbH Germany Bayer 04 Leverkusen Fußball GmbH Germany Bayer 04 Leverkusen
    [Show full text]
  • Steven Sanders, Et Al. V. Bayer (AG) Aktiengesellschaft, Et Al. 03-CV-1546-Second Consolidated Amended Complaint
    Q,^.IGiNAL &&,iN 2i 4- L UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -_DOF x Consolidated Civil Action IN RE BAYER AG SECURITIES No. 03 CV 1546 (WHP) LITIGATION Class Action x 71 :n = SECOND CONSOLIDATED AMENDED COMPLAINT Jury Trial Demand MILBERG WEISS BERSHAD & SCHULMAN LLP Melvyn I. Weiss (MW-1392) Michael C . Spencer (MS-8874) Lee A. Weiss (LW-1130) Jennifer Sclar (JS-7313) One Pennsylvania Plaza New York, NY 10119 (212) 594-5300 Attorneys for Lead Plaintiff January 14, 2005 i • ' Table of Contents Page SUMMARY OF CLAIMS ...............................................................................................................2 JURISDICTION AND VENUE ...................................................................................................... 8 A. General Jurisdiction and Venue ............................................................................... 8 B. Subject Matter Jurisdiction Over Claims of Foreign Purchasers on Foreign Exchanges ................................................................................................................ 8 PARTIES .......................................................................................................................................12 RELEVANT EVENTS ..................................................................................................................14 A. Background of the Statin Market ...........................................................................14 B. FDA Approval and Introduction of Baycol; Early Safety Warnings
    [Show full text]
  • He Noble Path
    HE NOBLE PATH THE NOBLE PATH TREASURES OF BUDDHISM AT THE CHESTER BEATTY LIBRARY AND GALLERY OF ORIENTAL ART DUBLIN, IRELAND MARCH 1991 Published by the Trustees of the Chester Beatty Library and Gallery of Oriental Art, Dublin. 1991 ISBN:0 9517380 0 3 Printed in Ireland by The Criterion Press Photographic Credits: Pieterse Davison International Ltd: Cat. Nos. 5, 9, 12, 16, 17, 18, 21, 22, 25, 26, 27, 29, 32, 36, 37, 43 (cover), 46, 50, 54, 58, 59, 63, 64, 65, 70, 72, 75, 78. Courtesy of the National Museum of Ireland: Cat. Nos. 1, 2 (cover), 52, 81, 83. Front cover reproduced by kind permission of the National Museum of Ireland © Back cover reproduced by courtesy of the Trustees of the Chester Beatty Library © Copyright © Trustees of the Chester Beatty Library and Gallery of Oriental Art, Dublin. Chester Beatty Library 10002780 10002780 Contents Introduction Page 1-3 Buddhism in Burma and Thailand Essay 4 Burma Cat. Nos. 1-14 Cases A B C D 5 - 11 Thailand Cat. Nos. 15 - 18 Case E 12 - 14 Buddhism in China Essay 15 China Cat. Nos. 19-27 Cases F G H I 16 - 19 Buddhism in Tibet and Mongolia Essay 20 Tibet Cat. Nos. 28 - 57 Cases J K L 21 - 30 Mongolia Cat. No. 58 Case L 30 Buddhism in Japan Essay 31 Japan Cat. Nos. 59 - 79 Cases M N O P Q 32 - 39 India Cat. Nos. 80 - 83 Case R 40 Glossary 41 - 48 Suggestions for Further Reading 49 Map 50 ■ '-ie?;- ' . , ^ . h ':'m' ':4^n *r-,:«.ria-,'.:: M.,, i Acknowledgments Much credit for this exhibition goes to the Far Eastern and Japanese Curators at the Chester Beatty Library, who selected the exhibits and collaborated in the design and mounting of the exhibition, and who wrote the text and entries for the catalogue.
    [Show full text]
  • Notes to the Consolidated Financial Statements of the Bayer Group
    Five-Year Summary Bayer Annual Report 2018 Five-Year Summary 2014 2015 2016 2017 2018 Bayer Group (€ million) Sales 41,339 46,085 34,943 35,015 39,586 EBITDA1 8,315 9,573 8,801 8,563 10,266 1 EBITDA before special items 8,685 10,256 9,318 9,288 9,547 1 EBITDA margin before special items (in %) 21.0 22.3 26.7 26.5 24.1 EBIT1 5,395 6,241 5,738 5,903 3,914 1 EBIT before special items 5,833 7,060 6,826 7,130 6,480 Income before income taxes 4,414 5,236 4,773 4,577 2,318 Net income (from continuing and discontinued operations) 3,426 4,110 4,531 7,336 1,695 1 Earnings per share (from continuing and discontinued operations) (€) 4.14 4.97 5.44 8.29 1.80 1 Core earnings per share (from continuing operations) (€) 5.89 6.82 6.67 6.64 5.94 Net cash provided by operating activities (from continuing and discontinued operations) 5,810 6,890 9,089 8,134 7,917 Net financial debt 19,612 17,449 11,778 3,595 35,679 2 Capital expenditures (as per segment table) 2,484 2,554 2,627 2,418 2,564 Bayer AG Total dividend payment 1,861 2,067 2,233 2,402 2,611 Dividend per share (€) 2.25 2.50 2.70 2.80 2.80 Innovation Research and development expenses (€ million) 3,537 4,274 4,405 4,504 5,246 Ratio of R&D expenses to sales – Pharmaceuticals (%) 15.6 16.0 16.7 16.2 15.5 Ratio of R&D expenses to sales – Crop Science (%) 10.3 10.7 11.7 11.7 13.0 Employees in research and development3 13,900 14,753 14,213 14,041 17,275 Employees 3 Number of employees (Dec.
    [Show full text]
  • Glaxosmithkline Aims to Divest Many OTC Brands
    OTC11-02-11p1&28FIN.qxd 8/2/11 11:52 Page 1 11 February 2011 COMPANY NEWS 3 GlaxoSmithKline aims to Valeant expands in CEE 3 with PharmaSwiss deal J&J loses sales of US$1.1bn 4 Boots faces up to tough market 5 divest many OTC brands Key brands boost Novartis OTC sales 6 GSK consumer races ahead 7 laxoSmithKline intends to divest non- to divest the non-core brands as soon as pos- Taisho holds steady in weak market 8 Gcore OTC brands with combined an- sible – hopefully before the end of the year – Vicks shipments lift OTC at P&G 9 nual sales of £500 million (C593 million). depending on buyer interest. Perrigo plans spring Allegra launch 10 Chief executive officer Andrew Witty said The announcement came as GlaxoSmith- Consumer Care grows at Merck & Co 11 the move would enable the company’s Con- Kline reported a 7% rise – 5% at constant ex- Omega reports strong quarter 12 sumer Healthcare division to focus more effec- change rates – in 2010 sales at the Consumer Winter woes hit Boiron 13 tively on its “priority or global” brands as well Healthcare division to £5.01 billion. Sales in Pfizer wants Consumer 14 as its operations in emerging markets. Consumer Healthcare’s OTC Medicines busi- to prove worth A spokesperson for GlaxoSmithKline told ness grew by 5% – 3% at constant exchange OTC bulletin that the company was currently rates – to £2.46 billion. GENERAL NEWS 15 compiling the lists of priority and non-core OTC brands, and hoped to release more details Recent deals with Meda and Valeant Perrigo faces lawsuit over 15 in the second quarter of the year.
    [Show full text]
  • PADAM and JAVALI MODULE 1 Padam, Atreasure Trove for Abhinaya
    PAPER 13 PADAM AND JAVALI MODULE 1 Padam, Atreasure trove for Abhinaya. Padams are scholarly compositions, mostly monologues. Padams stand on their own merit, with their pristine music and emotion-packed lyrics. It is a musical monologue which resembles a kirtana in structure and propagates the sentiment of love for God through the innumerable aspects of Nayika– nayaka bhava / नायक-नाययका. It is a scholarly composition with a perfect blend of Sangita and Sahitya / संगीत तथा साहित्य. The padams / ऩदम ् treat various aspects of the nayika nayaka bhava dwelling on shringara (the erotic sentiment), depicting the longings of a nayika for union with her nayaka or beloved. The bhakti school of poetry has found its finest expression in padams composed mainly in the medieval period. Kshetrayya / क्षत्रिय is one of the greatest of composers of Padam. Madhurabhava bhakti / मधुरभाव भक्तत is the main concept. It admits to outward shringara / �ींगार with an inner philosophical meaning. The nayika is the soul (jivatma / जीवात्मा) longing for union with the nayaka (Paramatma / ऩरमात्मा) and helped by the sakhi (Guru) in her endeavour. The Gita Govinda of Jayadeva is the earliest work which deals with this concept. 1 Structure A padam comprises of a pallavi, anupallavi and charanam. It may have multiple charanas / चरण. In the original compositions, there are not many sangatis. Those we hear now have been added over the years. The mudra (signature) of the composer may appear in the pallavi, anupallavi or in the last charanam. Language Padams are scholarly compositions in Telugu and Tamil.
    [Show full text]
  • New Technology in Multi-Sensory Public
    MULTI-SENSORY SITES OF EXPERIENCE: PUBLIC ART PRACTICE IN A SECULAR SOCIETY SUBMITTED IN FULL FULFILLMENT REQUIRED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY FACULTY OF THE CONSTRUCTED ENVIRONMENT SCHOOL OF ARCHITECTURE AND DESIGN RMIT UNIVERSITY Anton Glenn Hasell B. Ec, Dip. Ed, B.F.A, P-G Dip F.A, M.F.A September 2002 1 Abstract Western secular societies have come to celebrate the individual within his or her community. Secular society has been shaped to fit the maximum freedoms and rights that are compatible within the compromise that communal life impose upon its members. Earlier communities in both Europe and Asia were bounded by religious practices that privileged the communal perspective over that of the individual. Rituals brought people together and the places in which these rituals were enacted, the temples and cathedrals so central to communal life, were places of complex and powerful multi-sensory experience. It is within such stimulating experience that people recognize themselves as vibrant parts to a greater whole. Artists who work in public-space commissioned works, such as myself, are repeatedly invited to create works of art that signify and celebrate the forms and images that bring the community together. Such communal-building work attempts to countervail the drive to ever greater individual freedoms in secular society. Artists are placed in a difficult position. The most recent developments in computer technology have been used to re-invent the bell. The reinvented bell has become a fundamental element in new bell-sculpture installation works. This thesis develops a context for the use of bells in contemporary public-space design.
    [Show full text]
  • Annual Report 1998 Expertise with Responsibility
    Annual Report 1998 Expertise with Responsibility Bayer is a diversified, international chemicals and health care group. We offer our customers a wide variety of products and services in areas ranging from pharmaceuticals and crop protection to plastics, specialty chemicals and imaging technologies. Bayer is research-based and aims for technological leadership in its core activities. Our goals are to steadily increase corporate value and generate a high value added for the benefit of our stockholders, our employees and the community in every country in which we operate. We believe that our technical and commercial expertise involves a responsibility to work for the common good and contribute to sustainable development. Bayer: Success through Expertise with Responsibility. Bayer Key Data Bayer Group 1998 1997 Change in % Sales DM million 54,884 55,005 – 0.2 Operating result DM million 6,151 6,018 + 2.2 Income before income taxes DM million 5,336 5,108 + 4.5 Net income DM million 3,157 2,941 + 7.3 Gross cash flow DM million 6,602 6,480 + 1.9 Stockholders’ equity DM million 24,991 23,923 + 4.5 Total assets DM million 57,216 54,170 + 5.6 Capital expenditures DM million 5,165 4,559 + 13.3 Employees at year end 145,100 144,600 + 0.3 Personnel expenses DM million 15,854 15,442 + 2.7 Research and development expenses DM million 3,920 3,878 + 1.1 Bayer AG 1998 1997 Change in % Total dividend payment DM million 1,461 1,388 + 5.3 Dividend per share DM 2.00 1.90 + 5.3 Tax credit DM 0.65 0.81 - 19.8 Published by Bayer AG, 51368 Leverkusen, This complete version of the Annual Report Germany is published in English and German.
    [Show full text]
  • Bayer Annual Report 2013 Bayer Annual Report 2013 11 for a Better Life for a Better Life
    » COVER PICTURE Annual Report 2013 Augmented Version ABOUT THE » Bayer: Science For A Better Life INTEGRATED REPORT » Key Data This year’s Annual Report ­combines­our­financial­and­ » Chairman’s Letter our sustainability reporting for­the­first­time.­On­page­ » FOR A BETTER LIFE 28-29­you­can­find­further­ » Fighting cancer 10 information about this report » Safeguarding nutrition 16 and­learn­how­to­use­it. » Conserving resources 22 » TO OUR STOCKHOLDERS » Executive Council 30 » Report of the Supervisory Board 32 » Investor Information 37 01 » COMBINED MANAGEMENT REPORT OF THE BAYER GROUP AND BAYER AG 45 Report on Economic Position 151 » Overview of Sales, Earnings and Financial Position 152 » Business Development by Subgroup, Segment and Region 156 » Earnings; Asset and Financial Position of the Bayer Group 170 » Earnings; Asset and Financial Position of Bayer AG 181 02 » CONSOLIDATED FINANCIAL STATEMENTS OF THE BAYER GROUP 227 » RESPONSIBILITY STATEMENT 330 » INDEPENDENT AUDITORS’ REPORT 331 » INDEPENDENT ASSURANCE REPORT 333 » For direct access 03 FURTHER INFORMATION 336 to a chapter, simply click on its name. » Financial Calendar » Masthead, Disclaimer » TABLE OF CONTENTS Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, we set trends in research- intensive areas. Our products and services are designed to benefit people and improve their quality of life. At the same time we aim to create value through innovation, growth and high earning power. We are committed to the principles of sustainable development and to our social and ethical responsi- bilities as a corporate citizen.
    [Show full text]
  • Quoted from Wikipedia.Com, November 2010
    Quoted from Wikipedia.com, November 2010 Singing bowls (also known as Himalayan bowls, rin gongs, medicine bowls, Tibetan bowls or suzu gongs in Japan) are a type of bell, specifically classified as a standing bell. Rather than hanging inverted or attached to a handle, standing bells sit with the bottom surface resting. The sides and rim of singing bowls vibrate to produce sound. Singing bowls were traditionally used throughout Asia as part of Bön and Tantric Buddhist sadhana. Today they are employed worldwide both within and without these spiritual traditions, for meditation, trance-induction, relaxation, healthcare, personal well-being and religious practice. Singing bowls were historically made in Tibet, Nepal, India,[1] Bhutan, China, Japan and Korea.[citation needed] Today they are made in Nepal, India, Japan and Korea. The best known type are from the Himalayan region and are often termed Tibetan singing bowls. Origins, history and usage In Buddhist practice, singing bowls are used as a support for meditation,[2] trance induction and prayer. For example, Chinese Buddhists use the singing bowl to accompany the wooden fish during chanting, striking it when a particular phrase in a sutra, mantra or hymn is sung. In Japan and Vietnam, singing bowls are similarly used during chanting and may also mark the passage of time or signal a change in activity. As Perry[3] (1996) and Jansen[4] (1992) state, little is known in western scholarship regarding Himalayan singing bowls. It is likely they were used in rituals, having a specific function like other instruments (such as the ghanta, tingsha, and shang).
    [Show full text]
  • Prapatti an Article by Sri Karalappakam Anantha Padhmanabhan
    Page 1 of 10 Prapatti An article by Sri Karalappakam Anantha Padhmanabhan Sriman nArAyaNA out of His great compassion towards the baddha jIvAtmAs propagates vedAs and allied sAstrAs, which are the only way through which they can possibly know about Him & the ways to reach Him. The ultimate and final essence of sAstrAs is that Sriman NArAyaNA is the sarIrI and, all chit & achit are His sarIrA. This eternal sarIra sarIrI bhAvA is composed of the following three things: 1. AdheyatvA (i.e. being supported by a sarIrI): Existence of the sarIrA(body) is due to the sarIrI i.e. sarIrI supports the sarIrA. In other words, if sarIrI ceases to exist, sarIrA also ceases to exist. 2. niyamyatvA (i.e. being controlled by a sarIrI): Not only that sarIrA derives its existence from a sarIrI, it is also being controlled by the sarIrI. So, sarIrA acts as per the will/desires of sarIrI. 3. seshatvA (i.e. existing for the pleasure of sarIrI): Not only that sarIrA is supported & controlled by sarIrI, it exists only for the pleasure of sarIrI, i.e. sarIrI is sarIrA's Master. It is to be noted that the "sarIrI" needn't be physically present inside a "sarIrA". This is not a condition to be met out for the sarIra-sarIrI bhAvA to hold good. Thus Sriman NArAyaNA supports and controls all jIvAtmAs, and all the jIvAtmAs exist purely for His enjoyment. Thus, the very essential nature (svaroopam) of a jIvAtmA is to perform kainkaryam to Sriman NArAyaNA for His pleasure and performance of any other activity doesn't conform to its nature.
    [Show full text]
  • Esoteric Buddhist Ritual Objects of the Koryŏ Dynasty (936-1392): Vajra
    Esoteric BuddhistRitual Objectsof the KoryŏDynasty(936-1392): VajraSceptersand VajraBells NellyGeorgieva-Russ,AcademyofKoreanStudies The EsotericBuddhist tradition,knowninKoreaas milgyo ,or secretteaching,has playedimportant role in the history of KoreanBuddhism.Esoteric cults andpractices relatedtoMahayana Buddhism were supposedly present on the Korean peninsula since the introduction of Buddhism in 372 CE. Sutras with esoteric content, such as the Bhaisajyaguru Sutra, the Saddharmapundarika Sutra, Suvarnaprabhasa Sutra etc.,as well as dharani sutras were widely spreadduring the Three Kingdoms period(300-668CE) 1.Esoteric Buddhism was supportedby the royal court bothinthe UnifiedSilla (668-935) and Kory ŏ (918-1392) periods in connection with hoguk pulgyo (Buddhism as National Protector), its rites called to miraculously protect the nation against foreign invaders. Esoteric Buddhism, more than any other Buddhist school, is concernedwith worldly needs thus establishing a link between Buddhist spirituality and secular powers. Nevertheless, the absence of an established esoteric school paralleling the ZhenyaninChina andShingonin Japan andthe unarticulatedpresence of Esoteric beliefs and practices within such all-pervadingly influential sects as S ŏn or Pure Land Buddhism inKorea has leadtothe marginal positionof this fieldinBuddhist studies,bothinKorea andthe West.At the same time,eventhe scarce data onearly KoreanBuddhism reveals its profound influenceduringtheSillaandKory ŏdynasties. Animportantfactor in the practice ofesoteric Buddhism during the Koryŏis the probable existence of two esoteric sects: the Sinin (Mudra) school and the Ch’ongji (Dhārani) school. Both denominations are first encountered in Samguk Yusa ,according to whichthe founding of the Ch’ongji school is associated with the Silla monk Hyet’ŏng. 2 Nevertheless, the main reliable historical data about this school is a number of records in Koryŏ-sa referring tothe twelve century and later,about temples belonging to the Ch’ongji sect where esoteric rituals were conducted.
    [Show full text]